8-K: Tactile Medical Reports Solid Q3 2024 Results and Authorizes $30 Million Share Repurchase Program

Tactile Medical announced a 5% year-over-year revenue increase for Q3 2024, alongside a new $30 million share repurchase program.

Summary

• Tactile Medical reported a 5% increase in total revenue for the third quarter of 2024, reaching $73.1 million, compared to $69.6 million in the same period last year.
• Lymphedema product revenue grew by 4%, while airway clearance product revenue increased by 10% year-over-year.
• Net income for the quarter was $5.2 million, a decrease from $22.3 million in Q3 2023, primarily due to the impact of last year's valuation allowance release on prior-year income tax.
• Adjusted EBITDA for the quarter was $10.7 million, up from $7.7 million in the prior year.
• The company's operating cash flow year-to-date is $24.3 million, compared to $17.5 million in the prior year period.
• Tactile Medical ended the quarter with $82.1 million in cash and cash equivalents.
• A share repurchase program of up to $30 million was authorized, effective from October 30, 2024, to October 31, 2026.
• The company updated its 2024 revenue outlook to a range of $292 million to $295 million, representing a 6% to 8% year-over-year growth.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to solid revenue growth and a share repurchase program, but tempered by a significant decrease in net income and a slight downward revision of revenue guidance.

Positives

• The company experienced solid gross margin expansion, with a gross margin of 75.0% compared to 70.9% in the same quarter last year.
• Profitability continued to improve, with adjusted EBITDA increasing to $10.7 million.
• The company achieved double-digit growth in both commercial and VA lymphedema channels.
• The launch of the next-generation lymphedema therapy platform, Nimbl, is a positive step for future growth.
• The company is generating strong free cash flow, which is expected to continue.
• The share repurchase program is a positive use of cash that aligns with the company's conviction in its business trajectory.
• The company has a strong cash position of $82.1 million.

Negatives

• Net income decreased significantly to $5.2 million from $22.3 million in Q3 2023, primarily due to the impact of last year's valuation allowance release on prior-year income tax.
• Operating expenses increased by 16% to $48.0 million, compared to $41.4 million in the third quarter of 2023.
• The company's revenue was impacted by changes in policy interpretation from Medicare administrators and DME buying patterns within the airway clearance business.
• The company has revised its full year 2024 revenue guidance down slightly from $293-$298 million to $292-$295 million.

Risks

• Changes in policy interpretation from Medicare administrators could continue to impact revenue.
• DME buying patterns within the airway clearance business could pose a risk to future revenue.
• The company faces potential risks related to its ability to obtain reimbursement from third-party payers.
• The company is subject to the impacts of inflation, rising interest rates, and potential recession.
• Intense competition and the entry of new competitors and products could impact the company's market share.
• The company is subject to compliance with and changes in federal, state and local government regulation.
• The company faces risks related to the loss or retirement of key executives.

Future Outlook

The company updated its 2024 financial outlook and now expects full year 2024 total revenue in the range of $292 million to $295 million, representing growth of approximately 6% to 8% year-over-year.

Management Comments

• In the third quarter, we delivered solid gross margin expansion, drove continued improvements in profitability, and achieved double-digit growth in both our commercial and VA lymphedema channels, said Sheri Dodd, President and Chief Executive Officer of Tactile Medical.
• While pleased with this performance, our revenue was impacted by changes in policy interpretation from Medicare administrators and DME buying patterns within our airway clearance business.
• We are taking a concerted approach to fortify our sales channels, simplify our front and back-office work through technology modernization, and amplify the voice of our patients and providers through product and service innovation.
• Finally, we are increasingly benefiting from generating free cash flow, a trend we expect to continue.
• We believe this strategic near-term use of cash aligns with our conviction in the trajectory of our business and our ability to execute our financial and operational initiatives.

Industry Context

The announcement reflects the ongoing challenges and opportunities within the medical technology sector, particularly in the areas of chronic disease management and home healthcare. The company's focus on innovation and strategic investments aligns with broader industry trends towards patient-centric care and cost-effective solutions.

Comparison to Industry Standards

• Tactile Medical's 5% revenue growth is moderate compared to some high-growth medical device companies, but it is solid considering the challenges faced with Medicare policy changes.
• Companies like InMode (INMD) have shown higher growth rates in the aesthetic medical device space, while others like ResMed (RMD) in respiratory care have seen more consistent growth.
• The adjusted EBITDA margin of Tactile Medical is competitive with other medical device companies of similar size, but it is important to note that the company's net income was significantly impacted by a one-off tax event.
• The share repurchase program is a common strategy among mature companies with strong cash flow, similar to what companies like Medtronic (MDT) have implemented.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's focus on increasing shareholder value.
• Employees may benefit from the company's continued growth and investment in technology.
• Patients will benefit from the launch of new products and the company's commitment to improving access to care.
• Suppliers may benefit from the company's continued growth and demand for its products.
• Creditors may benefit from the company's strong cash position and ability to meet its obligations.

Next Steps

• The company will continue to execute its commercial strategy, including the launch of the Nimbl platform.
• The company will continue to evaluate various investment opportunities to drive growth and increase shareholder value.
• The company will execute the share repurchase program.
• Management will host a conference call to discuss the results of the quarter.

Key Dates

Keywords

Tactile Medical, Lymphedema, Airway Clearance, Share Repurchase, Medical Technology, Financial Results, EBITDA, Revenue, Healthcare, Nimbl